Encorafenib, a new-generation BRAF inhibitor, has been approved by FDA for the 
treatment of melanoma in combination with binimetinib. However, the mechanism of 
the drug works in colorectal cancer (CRC) is still unclear. In this study, the 
suppression of growth of CRC cells by encorafenib was investigated. The effects 
of treatment of encorafenib on pathways linked to cancer were studied, and the 
effective inhibition of cell proliferation was documented. Our findings showed 
that cell migration was inhibited by encorafenib through a likely involvement of 
MPP and TIMP modulation. Furthermore, encorafenib treatment also induced cell 
cycle arrest. In addition, induction of apoptosis in CRC cells by elevating 
levels of PUMA. These observations indicate the potential therapeutic efficacy 
of encorafenib on CRC.